Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Alvotech ( (ALVO) ).
On February 5, 2026, Alvotech reported positive top-line results from a pivotal pharmacokinetic study of AVT80, its proposed subcutaneous biosimilar to Takeda’s Entyvio (vedolizumab), used to treat ulcerative colitis and Crohn’s disease. The randomized, double-blind, three-arm trial in healthy adults met all primary endpoints for pharmacokinetic similarity, as well as assessing safety, tolerability and immunogenicity, and is considered by regulators as pivotal to demonstrating clinical similarity for both AVT80 (subcutaneous) and AVT16 (intravenous), Alvotech’s twin Entyvio biosimilar programs. The outcome marks a key development milestone that supports future regulatory submissions and strengthens Alvotech’s positioning in the high-value inflammatory bowel disease biologics market, where Entyvio generated about $6.4 billion in global net revenue in 2025, potentially paving the way for a competitive biosimilar entrant once approvals are obtained.
The most recent analyst rating on (ALVO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score is driven by financial instability, bearish technical indicators, and regulatory challenges impacting short-term outlook. While strategic investments and historical growth are positives, significant risks remain.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotechnology company focused solely on developing and manufacturing biosimilar medicines, with two biosimilars to Humira and Stelara already approved and marketed in multiple regions. The company is building a diversified pipeline of nine disclosed biosimilar candidates targeting autoimmune, eye, bone, respiratory and oncology indications, and distributes its products through an extensive network of commercial partners across the US, Europe, Japan, China, Latin America, Africa, the Middle East and Asia-Pacific, positioning itself as a cost-effective alternative provider in the biologics market.
Average Trading Volume: 502,188
Technical Sentiment Signal: Sell
Current Market Cap: $1.52B
Learn more about ALVO stock on TipRanks’ Stock Analysis page.